Core Technology Platforms

Abelzetaâ??s competitive advantage lies in its specialized technology platforms designed to overcome the limitations of first-generation cell therapies. These platforms focus on enhancing the persistence, safety, and efficacy of Chimeric Antigen Receptor (CAR) T-cell treatments.

Bispecific CAR-T Platform

Traditional CAR-T therapies target a single antigen, which can lead to treatment failure through "antigen escape." Abelzeta has developed a bispecific platform that allows a single CAR-T cell to target two different antigens simultaneously. This dual-targeting approach is designed to reduce the likelihood of tumor escape and improve the durability of patient responses, particularly in hematological malignancies.

"Armored" CAR-T and Solid Tumor Solutions

One of the most significant challenges in oncology is the application of CAR-T therapy to solid tumors, which present a hostile immunosuppressive microenvironment. Abelzetaâ??s "Armored" CAR-T platform involves engineering cells that not only target tumor antigens but also secrete cytokines or blockers to neutralize the tumorâ??s defenses. This enhances the ability of the T-cells to penetrate and remain active within solid tumor masses.

Proprietary Manufacturing and CMC

Abelzeta utilizes an automated, closed-system manufacturing process. This infrastructure is critical for maintaining consistency in cell product quality while reducing the risk of contamination and lowering production costs. By controlling the Chemistry, Manufacturing, and Controls (CMC) process in-house, Abelzeta ensures a rapid turnaround time for patient-specific therapies.

Product Pipeline and Services

Abelzetaâ??s pipeline is divided between treatments for hematological (blood) cancers and solid tumors, with several candidates currently in various stages of clinical trials.

Hematological Malignancies

1. C-CAR039 (CD19/CD20 Bispecific CAR-T): This is Abelzetaâ??s lead candidate for B-cell non-Hodgkin lymphoma (B-NHL). By targeting both CD19 and CD20, C-CAR039 has demonstrated high overall response rates (ORR) and complete response (CR) rates in clinical trials. It was granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations by the U.S. FDA, highlighting its potential to address unmet needs in patients who have failed prior lines of therapy.

2. C-CAR066 (CD20 CAR-T): Targeted specifically at patients with B-cell malignancies who have relapsed or are refractory to CD19-targeted therapies. This product serves as a secondary line of defense in the cell therapy landscape, providing an alternative for patients whose tumors no longer express the CD19 antigen.

Solid Tumor Programs

1. C-CAR031 (GPC3-targeted CAR-T): Developed for the treatment of Hepatocellular Carcinoma (HCC), the most common form of liver cancer. This program is notable for its partnership with AstraZeneca. C-CAR031 utilizes a specific design to target Glypican-3 (GPC3), a protein highly expressed in liver cancer cells.

2. C-CAR084 (Axl-targeted CAR-T): This candidate focuses on targeting Axl, a cell surface receptor tyrosine kinase associated with poor prognosis and epithelial-to-mesenchymal transition in various solid tumors, including lung cancer.

Research and Development Services

Beyond its internal pipeline, Abelzeta functions as an innovation hub in the biopharmaceutical space. The company engages in: * Collaborative Development: Partnering with global pharmaceutical entities (such as AstraZeneca and Janssen) to co-develop and commercialize cell therapy assets. * Clinical Trial Management: Operating multi-center trials across the US and China, leveraging its dual-regional presence to accelerate patient recruitment and regulatory filings.

Manufacturing Facilities and Infrastructure

Abelzeta maintains state-of-the-art facilities that adhere to both U.S. FDA and China NMPA (National Medical Products Administration) Good Manufacturing Practice (GMP) standards.

• Rockville, Maryland Facility: Serves as the hub for U.S. clinical operations and late-stage R&D.
• Shanghai Integrated Center: A massive facility dedicated to large-scale clinical production and commercialization preparation. This site includes advanced cleanrooms and specialized laboratories for cell processing and quality control.

Market Position and Strategic Outlook

Abelzeta distinguishes itself through its "China-to-Global" strategy. By initiating early-stage clinical trials in Chinaâ??where the regulatory pathway for cell therapy has historically allowed for rapid data generationâ??the company can quickly validate its constructs before expanding into the U.S. and European markets.

As the MedTech and Biotech sectors shift toward personalized medicine, Abelzetaâ??s focus on autologous (patient-derived) cell therapies places it at the forefront of the industry. The company is currently transitioning from a research-heavy entity to a commercial-ready organization, focusing on the rigorous data required for Biologics License Applications (BLA). Through its combination of bispecific targeting, solid tumor innovation, and robust in-house manufacturing, Abelzeta is positioned to be a significant player in the next generation of cancer immunotherapy.